News >

Targeting Tumor Vasculature in Ovarian Cancer

Angelica Welch
Published: Wednesday, Dec 27, 2017

Robert L. Coleman, MD

Robert L. Coleman, MD
Angiogenesis inhibition is a process for tumor survival that has been known for many years, says Robert L. Coleman, MD. In ovarian cancer, antiangiogenesis agents have shown particular benefit, as they target tumor vascular biology.

, Coleman, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discussed targeting tumor vasculature and angiogenesis in ovarian cancer.

OncLive: Please provide an overview of your lecture on targeting tumor vasculature in ovarian cancer.

Coleman: I started out with a reference from 1907 in Lancet, where there was a question posed looking at the vasculature around cancers—asking why they were there, what role they play, and how to take care of it. I used that as an opening because it was more than a century ago that we recognized there was some relationship, and it was only about half of a century since we started to understand why those processes happen. Even today, it’s a well-acknowledged factor of tumor biology, and how we are approaching treatment is developing science.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication